Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397667 | 0.88 | CES2 (0.44) | CES2MEN1KMT2ANQO2HSD17B1 | |
| SCHEMBL1599382 | 0.85 | ALDH1A1 (0.59) | CES2MEN1KMT2ANQO2HSD17B1 | |
| SCHEMBL102484 | 0.85 | ALDH1A1 (0.57) | CES2MEN1KMT2ANQO2KIF11 | |
| SCHEMBL3685920 | 0.85 | ESR1 (0.57) | CES2MEN1KMT2ANQO2HSD17B1 | |
| SCHEMBL17141574 | 0.83 | MEN1 (0.44) | CES2MEN1KMT2ANQO2KIF11 | |
| SCHEMBL2001354 | 0.81 | CES2 (0.55) | CES2MEN1KMT2ANQO2TMPRSS4 | |
| SCHEMBL187014 | 0.80 | NQO2 (0.61) | CES2MEN1KMT2ANQO2KIF11 | |
| SCHEMBL16648820 | 0.78 | ESR1 (0.43) | CES2HSD17B1HSD17B2ARCYP2C9 | |
| SCHEMBL30708496 | 0.78 | ESR1 (0.43) | CES2HSD17B1HSD17B2ARCYP2C9 | |
| SCHEMBL25933574 | 0.78 | ESR1 (0.64) | CES2MEN1KMT2ANQO2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598901-A1 | PYRROLIDINE AND IMIDAZOLIDINE BASED DNA POLYMERASE THETA INHIBITORS AND USE THEREOF | Thomas Jefferson University (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-116655497-B | Amidine derivative compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-06-03 | — | — | CN | disclosed |
| EP-4484407-A2 | (METH)ACRYLATE COMPOUND, ADDITIVE FOR OPTICAL RESIN, OPTICAL ELEMENT, AND OPTICAL DEVICE | NIKON CORPORATION (JP) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024076964-A1 | PYRROLIDINE AND IMIDAZOLIDINE BASED DNA POLYMERASE THETA INHIBITORS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023160509-A1 | AMIDINE DERIVATIVE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-08-31 | — | — | WO | disclosed |
| CN-116655497-A | Amidine derivative compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-08-29 | — | — | CN | disclosed |
| US-11142636-B2 | (Meth)acrylate compound, additive for optical resin, optical element, and optical device | NIKON CORPORATION (JP) | 2021-10-12 | — | — | US | disclosed |
| US-20190322857-A1 | (METH)ACRYLATE COMPOUND, ADDITIVE FOR OPTICAL RESIN, OPTICAL ELEMENT, AND OPTICAL DEVICE | NIKON CORPORATION (JP) | 2019-10-24 | — | — | US | disclosed |
| EP-1716116-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060167324-A1 | High-purity (fluoroalkyl)benzene derivative and process for producing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080340-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1500641-A1 | HIGH-PURITY (FLUOROALKYL)BENZENE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-5629406-A | AMINO ACID DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-4347387-A | ISOMERIZATION OF 7-HYDROXYGERANYLAMINES OR 7-HYDROXYNERYLAMINES, PALLADIUM-PHOSPHINE CATALYST, ACIDOLYSIS | TAKASAGO PERFUMERY CO., LTD. (JP) | 1982-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | GPR119, SLC5A1, AADAC | CES2 382/4885MEN1 2841/4885KMT2A 1146/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CES2 3025/4885MEN1 3295/4885KMT2A 4267/4885 |
| US-20060167324-A1 | High-purity (fluoroalkyl)benzene derivative and process for producing the same | HBB, AFF4, AFF2 | CES2 2075/4885MEN1 4285/4885KMT2A 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.